News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Sandoz Enters US Immunology Market With Launch of Hyrimoz® (Adalimumab-adaz) High-concentration Formulation
Monday, July 03, 2023Sandoz a global leader in generic pharmaceuticals and biosimilars has announced the launch of the citratefree highconcentration formulation HCF of its biosimilar Hyrimoz adalimumabadaz injection in the United States starting July
Tonix Pharmaceuticals Successfully Acquires Two FDA-Approved Migraine Products Already in the Market
Monday, July 03, 2023Tonix Pharmaceuticals Holding Corp Nasdaq TNXP and its subsidiary Tonix Medicines Inc have recently completed the acquisition of two FDAapproved products from UpsherSmith Laboratories LLC
Zealand Pharma Reports Encouraging Findings From Phase 1 Trial of Multiple Ascending Dose With Amylin Analog ZP8396
Monday, July 03, 2023Zealand Pharma AS Nasdaq ZEAL CVRno a biotechnology company specializing in the development of innovative peptidebased medicines has announced the results of Part of a multiple ascending dose MAD trial for ZP This compound is a longacting amylin an...
Kissei Unveils Iktos AI Drug Discovery System
Monday, July 03, 2023Iktos a company specializing in Artificial Intelligence AI for new drug design has recently announced a collaboration with Kissei Pharmaceutical Co Ltd a prominent Japanese pharmaceutical company with a focus on urology kidneydialysis and unmet medic...
Sosei Heptares Administers First Dose in Phase I Trial Evaluating HTL0048149, a Novel GPR52 Agonist for Schizophrenia
Monday, July 03, 2023Sosei Group Corporation TSE has commenced a Phase I clinical trial for HTL HTL an innovative GPR agonist The drug is being developed for the treatment of schizophrenia and related neurological diseases
Aridis Pharmaceuticals Granted FDA Agreement for Single Confirmatory Phase 3 Study of AR-301 and Reveals Clinical Study Design
Saturday, July 01, 2023Aridis Pharmaceuticals Inc Nasdaq ARDS has received positive feedback from the FDA regarding its proposed Phase study for investigational monoclonal antibody candidate AR The study aims to evaluate the antibody as an adjunctive therapy in combinatio...
Temferon™ Granted Orphan Drug Designation by European Commission for Glioma Treatment
Friday, June 30, 2023Genenta Science NASDAQ GNTA has recently received Orphan Drug Designation ODD from the European Commission for their product Temferon which is being developed for the treatment of glioma specifically Glioblastoma Multiforme GBM ODD is granted to drug...
BioNTech and OncoC4 Collaborate on Phase 3 Trial for BNT316/ONC-392 Program in Metastatic NSCLC
Friday, June 30, 2023BioNTech SE Nasdaq BNTX and OncoC Inc have jointly announced the initiation of a Phase clinical trial for their novel antiCTLA antibody candidate BNTONC gotistobart The trial aims to evaluate the effectiveness and safety of BNTONC as a standalone th...
Societal CDMO and Civicascript Establish Master Service Agreement for CDMO Services
Friday, June 30, 2023Societal CDMO Inc NASDAQ SCTL has recently entered into a master service agreement MSA with CivicaScript a significant development in the contract development and manufacturing organization CDMO sector Societal CDMO is dedicated to addressing complex...
Alloy Therapeutics Introduces Exclusive Anticlastic™ Antisense Oligonucleotide Platform for the Creation of Powerful Genetic Medications
Thursday, June 29, 2023Alloy Therapeutics has recently unveiled its innovative AntiClastic Antisense Oligonucleotide AntiClastic ASO platform which enhances the properties of antisense therapeutics by employing optimally designed spatial conformation nucleic acids The comp...
